PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers
نویسندگان
چکیده
منابع مشابه
Resistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملresistance to her2-targeted therapy
production and approval of trastuzumab (herceptin®) for the treatment of metastatic breast cancer (mbc) was a millstone in antibody-based targeted therapy in the cancer treatment. however, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. the majority of patients who benefit from the drug acqui...
متن کاملHER2 Intermediate Breast Cancers.
To the Editor: We were interested to read the article by Gilcrease et al ‘‘Even low level Her2 expression may be associated with worse outcome in node positive breast cancer’’ that discusses the significance of low but nonnegative Her2 protein levels in the prognosis of breast cancer. As the authors note, the conventional immunohistochemical scoring system for Her2 includes cases with 1+ expres...
متن کاملTargeted therapy for HER2 positive breast cancer
INTRODUCTION Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45-55 years old (CDC.gov 2012). Although there continue to be enormously large numbers of disease incidence, deaths have been declining due to the disease with two hallmark time frames. The first occurred during the mid to late 1980's when ho...
متن کاملTargeted Therapy of HER2-Negative Breast Cancer.
Personalized and targeted treatments are the most discussed topics in oncology. However, how much personalized medicine is standard of care nowadays and how much is part of our hope for a better future? So far, only a few targeted therapies are available in daily practice for the treatment of human epidermal growth factor receptor 2 (HER2)-negative breast cancer. And even for these few targeted...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncogene
سال: 2015
ISSN: 0950-9232,1476-5594
DOI: 10.1038/onc.2015.406